Immunocytokines

View All

Latest-biotech-pharma-news-updates-for-ajinomot-pfizer-ikena-lilly-bright-peak
Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer’s Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing

Bright Peak Therapeutics, Ajinomoto Collaborates to Create Novel Immunocytokines Bright Peak Therapeutics has announced a research and licensing collaboration with Ajinomoto to incorporate AJICAP,  Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immuno...

Find More